Search results

53 results

• NEWSROOM

  UEG Week 2024

  We look forward to seeing you on booth 46 in Vienna from October 12 – 15, 2024!
• NEWSROOM

  Future starts here

  Plans for the future Falk Campus in Freiburg-Nord finalized.
• NEWSROOM

  NAFLD: Phase 2a proof of concept study of ZED1227

  Dr. Falk Pharma and Zedira announce trial start for the treatment of non-alcoholic fatty liver disease. First patient enrolled in April.
• NEWSROOM

  UEG Week 2022

  Join us from October 8 – 11 in Vienna on booth no. 43 or virtually!
• NEWSROOM

  First patient treated in phase iib study of Naronapride in patients with gastroparesis

  Dr. Falk Pharma is committed to researching, developing, and launching innovative treatments for digestive and metabolic disorders. We do this both through our own internal teams, and also in…
• NEWSROOM

  Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy

  Collaboration Provides Takeda an Exclusive License to Develop and Commercialize ZED1227/TAK-227 in the United States and Other Countries Outside of Europe, Canada, Australia and China.
• NEWSROOM

  Renexxion Ireland’s European Partner, Dr. Falk Pharma GmbH, has Elected PPI-nonresponsive Symptomatic GERD as the Second Naronapride Indication to Develop and Commercialize in their Licensed Territories

  ROSCREA, Ireland, and FREIBURG, Germany (GLOBE NEWSWIRE) [February, 7, 2024]– Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to…